NYSE:PLX
Protalix BioTherapeutics Inc Stock News
$1.21
+0.0100 (+0.83%)
At Close: Apr 24, 2024
Protalix BioTherapeutics Announces Private Note Exchange
06:50am, Friday, 13'th Aug 2021
CARMIEL, Israel, Aug. 13, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization
Protalix Stock Is Trading Higher On Meeting Request To FDA For Fabry Disease Candidate Application
08:03am, Monday, 02'nd Aug 2021
Protalix BioTherapeutics Inc (NYSE: PLX) has submitted a Type A Meeting request to the FDA regarding PRX-102 Complete Response Letter it received in April. The FDA issued the response letter for
Protalix BioTherapeutics Announces Submission of Type A Meeting Request to the FDA
06:50am, Monday, 02'nd Aug 2021
CARMIEL, Israel, Aug. 2, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization
Protalix BioTherapeutics to Participate in a Fireside Chat on June 30, 2021
06:50am, Monday, 28'th Jun 2021
CARMIEL, Israel , June 28, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization
Protalix Beaten Down By Covid Logistics, But Continues To Show Good Data
07:33pm, Tuesday, 22'nd Jun 2021
Protalix shares were smashed in April on a CRL received from the FDA. The CRL made no mention of any data, but was simply a logistics issue. An FDA team could not travel to Israel to inspect Protalix
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
08:16pm, Saturday, 05'th Jun 2021
New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") (NYSE: PLX). Such inv
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
12:30am, Thursday, 03'rd Jun 2021
NEW YORK, June 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") (NYSE: PLX). Such investors are
Protalix Shares Hits 52-Week Low After Adverse Event Reported In Fabry Disease Trial With PRX-102
12:10pm, Wednesday, 02'nd Jun 2021
Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Farmaceutici S.p.A. have provided an update on the clinical development of pegunigalsidase alfa (PRX–102) for the proposed treatment of Fabry
CARMIEL, Israel and BOSTON, June 2, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commerc
Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q1 2021 Results - Earnings Call Transcript
02:34pm, Friday, 14'th May 2021
Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q1 2021 Results - Earnings Call Transcript
Protalix BioTherapeutics Reports First Quarter 2021 Financial Results and Business Update
06:50am, Friday, 14'th May 2021
CARMIEL, Israel, May 14, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization
Earnings Preview for Protalix BioTherapeutics
12:45pm, Thursday, 13'th May 2021
On Friday, May 14, Protalix BioTherapeutics (AMEX:PLX) will release its latest earnings report. Here is Benzinga's outlook for the company.
Protalix BioTherapeutics Provides Update on Complete Response Letter for Pegunigalsidase Alfa from the FDA
01:27pm, Wednesday, 28'th Apr 2021
CARMIEL, Israel, April 28, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization
Protalix Stock Falls After FDA Slaps CRL For PRX-102 Application In Fabry Disease
06:21am, Wednesday, 28'th Apr 2021
Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici, have received a Complete Response Letter (CRL) from the FDA related to the marke
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
01:50am, Wednesday, 28'th Apr 2021
CARMIEL, Israel and BOSTON, April 28, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commerc
